Objective: Lifestyle and genetic factors interact in the development of obesity and the metabolic syndrome. The molecular mechanisms underlying the beneficial dietary modifications are, however, unclear. We aimed to examine the effect of the longterm moderate weight reduction on gene expression in adipose tissue (AT) and to identify genes and gene clusters responsive to treatment and thereby likely contributing to the development of the metabolic syndrome. Design: Randomized controlled and individualized weight reduction intervention. Subjects: Forty-six subjects with impaired fasting glycemia or impaired glucose tolerance and features of metabolic syndrome, aged 6077 years were randomized either to a weight reduction (WR) (n ¼ 28) or a control (n ¼ 18) group lasting for 33 weeks. Measurements: Oral and intravenous glucose tolerance tests and subcutaneous AT biopsies were performed before and after the intervention. Gene expression of AT was studied using microarray technology in subgroups of WR (with weight reduction X5%, n ¼ 9) and control group (n ¼ 10). The results were confirmed using quantitative PCR. Results: In the WR group, glucose metabolism improved. Moreover, an inverse correlation between the change in S I and the change in body weight was found (r ¼ À0.44, P ¼ 0.026). Downregulation of gene expression (Po0.01) involving gene ontology groups of extracellular matrix and cell death was seen. Such changes did not occur in the control group. The tenomodulin-gene was one of the most downregulated genes (À39716%, Po0.0001). Moreover, its expression correlated with insulin sensitivity (r ¼ À0.34, P ¼ 0.005) before the intervention and with body adiposity both before (r ¼ 0.42, P ¼ 0.007) and after (r ¼ 0.30, P ¼ 0.056) the intervention. Conclusion: Genes regulating the extracellular matrix and cell death showed a strong downregulation after long-term weight reduction. This likely reflects a new stable state at the molecular level in AT. Further studies are warranted to elucidate the mechanisms of these genetic factors.
Introduction
Lifestyle and genetic factors interact in the development of obesity, the metabolic syndrome and progression to type 2 diabetes (T2DM). 1 These interactions are likely to be reflected in gene expression. The metabolic syndrome, characterized by central obesity, insulin resistance and abnormal glucose metabolism, 2 dyslipidemia and hypertension, predisposes to cardiovascular diseases 3 and T2DM. 4, 5 Besides insulin resistance, T2DM is preceded by impaired first-phase insulin secretion, which is an inherent feature of impaired fasting glycemia and impaired glucose tolerance. [6] [7] [8] Weight loss and beneficial dietary changes have been shown to decrease insulin resistance and prevent T2DM in overweight and obese individuals with impaired glucose tolerance, 6, [9] [10] [11] but the effect of these interventions on genome-wide gene expression is largely unknown. Several cross-sectional studies have shown that expression of individual genes in adipose tissue (AT) differs between obese and lean subjects. [12] [13] [14] AT secretes numerous active agents that contribute to fat storage and distribution, lipolysis, inflammation and insulin resistance, typical processes, which are involved in the pathogenesis of metabolic syndrome, T2DM and cardiovascular diseases. [15] [16] [17] [18] Weight reduction induces changes in the expression of various genes in AT. [19] [20] [21] [22] [23] A few studies have applied microarray technologies to study gene expression in AT of massively obese subjects either in comparison to lean subjects cross-sectionally 24, 25 or after short-term weight reduction. 26, 27 These studies have demonstrated downregulation in the expression of genes involved in inflammation and desaturation of fatty acids. 26, 27 In the present work, we studied the effect of long-term weight reduction on gene expression in AT of overweight or obese individuals with impaired fasting glycemia or impaired glucose tolerance and other features of the metabolic syndrome. We aimed to examine the effect of the long-term moderate weight reduction on gene expression in AT and to identify genes and gene clusters responsive to treatment and thereby likely contributing to the development of the metabolic syndrome.
Methods

Study design
Altogether 46 overweight or obese (BMI 28-40 kg m À2 ) subjects aged 40-70 years were recruited to the study. The subjects had impaired fasting glycemia (fasting plasma glucose concentration 5.6-7.0 mmol l À1 ) or impaired glucose tolerance (2-h plasma glucose concentration 7.8-11.0 mmol l
À1
) and at least two other features of the metabolic syndrome according to the Adult Treatment Panel III criteria 28 as modified by the AHA: 29 waist circumference 4102 cm (males)/488 cm (females), fasting serum triacylglycerol concentration X1.7 mmol l
, fasting serum HDLcholesterol o1.0 mmol l À1 (males)/o1.3 mmol l À1 (females), blood pressure X130/80 mm Hg. Subjects were randomized to a weight reduction (WR) (n ¼ 28) or a control group (n ¼ 18). The subjects were randomized at the Department of Clinical Nutrition (n ¼ 6 and 7, respectively) and at Kuopio Research Institute of Exercise Medicine (n ¼ 22 and 11, respectively). Subjects were matched for age, gender, BMI and status of glucose metabolism. The duration of the study varied between 32 and 38 weeks, the mean duration being 33.371.1 weeks. At screening, the health status and medical history of the subjects were examined by an interview. Laboratory examinations included measurements of the liver, kidney and thyroid function. All subjects kept a 4-day food record at baseline. At baseline and at the end of the intervention, the subjects underwent an oral glucose tolerance test (OGTT), frequently sampled intravenous glucose tolerance test (FSIGT), blood pressure measurement, anthropometric measurements (body weight, height, body composition (Bioelectrical impedance by STA/BIA Body Composition Analyzer, Akern Bioresearch Srl, Florence, Italy), waist circumference), AT biopsy and the following biochemical measurements: serum total and lipoprotein lipids, serum-free fatty acids and leptin (see Table 1 ). Blood pressure was measured twice on the right arm. The systolic and diastolic blood pressure was calculated as an average of the two measurements.
Weight reduction program
The subjects underwent a 12-week intensive weight reduction program. The minimum aim for the study, weeks 12-33 was to maintain the achieved weight loss. A clinical nutritionist gave detailed individual counseling based on an interview and 4-day food records kept by the subjects, aiming to decrease energy intake. The subjects kept 4-day food records two times during the intensive period and two times during weeks 20-32. After the 12-week program, the Weight reduction and gene expression in AT M Kolehmainen et al subjects met the clinical nutritionist for checking the food records. During this visit they also had a possibility to discuss possible difficulties they had in maintaining the weight. Subjects were asked to maintain their habitual level of physical exercise. Physical activity was monitored by a questionnaire at the beginning and the weeks 12 and 33 of the study.
Control group
The subjects in the control group were advised to continue their normal lifestyle during the study, and to keep their diet and exercise habits unchanged.
Glucose tolerance tests A 2-h OGTT was performed with 75 g of glucose. Blood samples for plasma glucose and serum insulin concentrations were drawn at 0, 30 and 120 min. The FSIGT was performed according to the Minimal Model method as described previously. 30 Insulin sensitivity index (S I ), glucose effectiveness (S G ) or acute phase insulin response to glucose (AIR) were calculated by the MINMOD Millennium software. 31 
Biochemical analyses
Biochemical analyses were performed in the Clinical Labora- 
RNA extraction
Total RNA from fat tissue was extracted using the TRIzol method followed by further purification with RNeasy Mini Kit columns according to the instructions provided by the manufacturers' (Invitrogen, Carlsbad, CA, USA and Qiagen, Valencia, CA, USA). The RNA concentration and the A 260 / A 280 ratio was measured using the NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), an acceptable ratio being 1.9-2.1.
Microarray probe preparation
The subjects were chosen for microarray experiments with the following criteria: 10 subjects from the WR group (n ¼ 28), who had the most pronounced weight reduction during the intervention and 10 subjects from the control group (n ¼ 18) with the most stable body weight during the study. Owing to technical problems in hybridization in one of the microarray chips, the samples from one of the subjects had to be excluded. Thus, the final number of subjects in the WR group was nine. Synthesis of biotin-labeled cRNA, hybridization to DNA microarrays (HG-U133 Plus 2.0 GeneChip) and detection of hybridized cRNA were performed as recommended by the manufacturer (Affymetrix Inc., Santa Clara, CA, USA).
Array data extraction and analysis
The arrays were scanned using HP GeneArray Scanner 3000 (Affymetrix Inc.). Primary data extraction was performed with Affymetrix GeneChip Operating Software. The software produces a one-cell intensity file that contains probe-level intensities for each chip. In the WR group one of the microarray chips was damaged during procedures, and consequently this subject was excluded from the analyses. The detection calls were calculated using the Affymetrix detection algorithm (Affymetrix, Statistical algorithms description document, 2002). Microarray data analysis was performed with dChip (www.dchip.org) software. All chips were normalized by using Invariant Set Normalization. 34 Model-Based Expression indexes 35 were calculated to Weight reduction and gene expression in AT M Kolehmainen et al summarize expression levels. A perfect match/mis-match difference model was used in Model-Based Expression indexes calculation, and outlier detection and correction was applied. After preprocessing steps, only genes that were called 'Present' in more than 50 percent of the replicates in at least one of the two time points were selected for further analysis. Differentially expressed genes were identified by using paired t-test with Po0.01 producing slightly different false discovery rate-values for the WR and control group. Differential expression of genes was examined within the groups. The set of differentially expressed genes was clustered with dChip's hierarchical clustering function. Before clustering, redundant probe sets were removed. Correlation was used as distance metric and the centroidlinkage method was applied. Finally, the differentially expressed genes were grouped by their Gene Ontology annotations.
Quantitative real-time PCR analysis of gene expression Quantitative real-time PCR (QPCR) was used for the confirmation of microarray gene-expression results. QPCR analyses were performed with TaqMan chemistry-based assays according to the instructions by the manufacturer by using ABI Prism 7500 analyzer (Applied Biosystems). The analysis for the relative quantity of a specific gene before and after the intervention in 27 subjects of the WR group and in 18 subjects of the control group was done in triplets.
A standard curve with points 0.025, 0.075, 0.3, 0.9 and 1.8 ng ml À1 of cDNA, respectively and calibrator at a concentration of 0.3 ng ml À1 was used on every plate. Relative quantity was analyzed using ABI Prism 7500 SDS software. Quantities on each plate were first corrected by the calibrator on the plate. The ratio of the amount per plate to the corresponding values of endogenous control was then calculated. The endogenous control was chosen using Human Endogenous Control Kit (Applied Biosystems). Among 11 possible candidates, cyclophilin A1 was chosen as the best candidate using cDNA synthesized from isolated human AT RNA.
Statistical analyses of the clinical data
The clinical data were analyzed using the SPSS software for Windows version 11.5.1 (SPSS Inc., Chicago, IL, USA). Data are given as mean7s.d., unless otherwise indicated. The normality of distributions of the study variables was tested with the Kolmogorov-Smirnov test with Lilliefors' significance correction. Logarithmic transformation was used to achieve normal distribution whenever needed (indicated in tables and/or figures). General Linear Model (GLM) for univariate analysis was used to test the difference in the baseline characteristics and in the changes among the groups. GLM for repeated measures was used for analyzing the interaction of time and group for each variable. Adjustments for age, gender and baseline body weight was performed, when appropriate. Paired samples T-test was used for comparing the baseline and endpoint measurements within the study group. Correlation analyses were done using Pearson's method. Partial correlation analysis with adjustment for weight at baseline and gender was used when appropriate. For the clinical and biochemical measurements Po0.05 was considered as statistically significant.
Ethical considerations
The study was in accordance with the standards of the Helsinki Declaration. The Ethics Committee of the District Hospital Region of Northern Savo and Kuopio University Hospital approved the study plan. All participants gave their written informed consent. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this study.
Results
Clinical and metabolic characteristics
The WR and control groups did not differ in any of the clinical variables at baseline ( Table 1 ). The 33-week intervention decreased the measures of body adiposity and fat distribution (Table 2) as well as fasting concentrations of plasma glucose and serum leptin in the WR group. The differences in the changes of anthropometric measures between the groups during the intervention were significant ( Table 2) . No significant differences in the changes in blood pressure, percent of body fat, concentrations of plasma glucose, serum insulin, serum total and lipoprotein lipids, S I , S G or acute phase insulin response to glucose were seen between the groups. The dietary data of the groups are shown in Table 3 . Dietary fat intake decreased as aimed at in the WR group. Fiber intake maintained at the level before the intervention in spite of the slight, although non-significant decrease in energy intake in the WR group, whereas fiber content of the diet clearly decreased in the control group.
In the WR group with some improvement in S I , the change in S I correlated inversely with the change in body weight after adjustment for baseline body weight (r ¼ À0.44, P ¼ 0.026). When combining the groups a similar, although lower correlation was found (r ¼ À0.23, P ¼ 0.057).
Weight reduction group
To select subjects for microarray analyses, the WR group was initially divided into those who lost X5% of their body weight (n ¼ 11, Group 1) and those who lost o5% (n ¼ 17, Group 2) ( Figure 1 , Table 4 ). Finally, nine (4 males/5 females) subjects from the Group 1 were included in the microarray analyses. They lost more weight than the rest of the WR group (7.872.9 vs 3.373.3%, P ¼ 0.002). They also had significant increase in S I and decrease in fasting serum insulin and in 2-h glucose concentrations, along with Weight reduction and gene expression in AT M Kolehmainen et al improvements in measures of body adiposity when compared to those selected for microarray analysis from the control group (n ¼ 10; 4 men/6 women) ( Table 4) .
Changes in gene expression in adipose tissue during the intervention
The expression of 105 genes (false discovery rate of 13.3% for the list of genes) in the WR group changed after the longterm moderate weight reduction program ( Table 5 ). The expression of 82% (86/105) of genes was downregulated in the WR group. Overall, the changes were modest, with fold changes ranging from 0.67 to 1.68. The genes were then analyzed for the cluster formation according to the Gene Ontology (GO) biological process categories (Table 5) . Gene Ontology clusters for biological processes were assessed for enrichment of genes into each cluster with Po0.001. Altogether seven Gene Ontology biological process clusters were found. These clusters were associated with the function of the extracellular matrix (ECM) and cell death. The expression of 62 genes changed in the control group (false discovery rate of 12.9% for the list of genes) and no clusters were formed (Supplementary Information). None of the genes were the same as in the WR group.
To confirm the microarray analysis, seven genes showing either up-or downregulation in the microarray analysis were tested by QPCR analyses (Figure 2 ). The QPCR analysis confirms and extends the data obtained by microarray for the whole population. In the WR group, significant downregulation was observed by QPCR with genes encoding tenomodulin-gene (TNMD) (À39716%, Po0.0001), ADAM12 (À15718%, P ¼ 0.023) and CCND2 (À24728%, P ¼ 0.040) ( Table 6) . Also the other genes confirmed by QPCR showed up-or downregulation as in microarray analyses (Table 6 ), but statistical significance was not reached in the QPCR analyses due to large inter-individual variation. In the control group, there were no significant changes in the genes confirmed by QPCR, except in PDGFRL (27735%,
One of the genes that showed most pronounced change during the intervention was the X-chromosomal TNMD gene. The transcript levels of the TNMD in AT in women before and after the intervention were about two times as high as in men (in women before the intervention 125745 AU, 99742 AU and after the intervention 110763 AU, 95732 AU for the WR and control group, respectively; in men 77732 AU, 51721 AU and 59727 AU, 53720 AU for the WR and control group, respectively; P ¼ 0.014À0.005 for gender difference within the group). This is in an agreement with the fact that the TNMD gene is located in the X-chromosome. Interestingly, the TNMD expression level correlated significantly with fasting serum insulin (Figure 3 ) adjusted for baseline body weight, when the WR and control groups were combined. When correlation was adjusted for both gender and baseline body weight, association remained for fasting serum insulin before (r ¼ 0.38, P ¼ 0.014) and after (r ¼ 0.29, P ¼ 0.066) the intervention. TNMD expression correlated also with S I (r ¼ À0.39, P ¼ 0.012) before the intervention as well as body fat mass and with lean body mass both before (r ¼ 0.42, P ¼ 0.007; r ¼ À0.42, P ¼ 0.007, respectively) and after the intervention (r ¼ 0.30, P ¼ 0.056; r ¼ À0.33, P ¼ 0.037, respectively).
Discussion
In the present study, we examined the effect of long-term moderate weight reduction on the gene expression in AT of overweight or obese subjects with the features of metabolic syndrome. Of the 105 genes responding to weight reduction, most were downregulated. The major gene clusters that were downregulated are involved in the function of the ECM and cell death. Weight reduction and gene expression in AT M Kolehmainen et al
As expected, in the present study, successful weight reduction resulted in an improvement in glucose and insulin metabolism and in measures of body adipocity. The improvement of S I was related to the degree of weight reduction. Individual genetic patterns also modify the effect of lifestyle factors on clinical and biochemical parameters, which explain the large inter-individual variation that was also seen in the present study. Such variation may complicate attempts to find patterns in gene expression resulting from dietary or other lifestyle changes, 36 especially in studies investigating outpatient clinic like programs. In the present study, we, therefore, focused on the changes in gene expression within the WR group after a moderate weight reduction. For gene-expression studies, we selected those subjects who responded best to weight reduction program. Weight loss and a reduction in fat mass decreased the expression of genes associated with the ECM in subcutaneous AT. Recent studies implicate that the ECM is involved in inflammation, 37 angiogenesis 38 and in the development of cardiovascular dysfunction in the metabolic syndrome and T2DM. 39, 40 The ECM contributes to cell-matrix interactions, and in the context of the metabolic syndrome, is characterized by abnormal glucose and lipid metabolism and inflammation in adipose and other tissues, the capability of the ECM to adapt to potentially toxic signals may be of importance for maintaining healthy homeostasis. 39 Since AT consists also of connective tissue, it is expected that the ECM components participate in remodeling and function of AT through cell-matrix interactions. It has been shown that, in addition to the ECM remodeling, matrix metalloproteinases and their inhibitors (MMP/TIMP system) regulate proteolytic events and adipogenesis during obesity-mediated fat mass development. 41 In addition, increased formation of the ECM constituents has been found in the white AT of rats, which were exposed to early-life under-nutrition and subsequently developed visceral obesity. 42 Transcription of the ECM constituents has recently been shown to be regulated by insulin in 3T3-L1 adipocytes. 43 In accordance with our study, long-term energy restriction has suppressed genes associated with the ECM in mice. 37 Weight reduction also decreased the expression of genes involved in terminal differentiation of fat cells, that is cell Figure 1 The weight loss (kg) in the weight reduction group divided to those who lost X5%~and to those who lost o5% ' of their original weight and in the control group m (mean7s.e.m.) with the measurements done in the main study visits. FSIGT ¼ frequently sampled intravenous glucose tolerance test, OGTT ¼ oral glucose tolerance test. The visit on week 20 was not included in the program of the control group, and thus, this point has been calculated as a mean of body weight measured at weeks 12 and 33.
Weight reduction and gene expression in AT M Kolehmainen et al death. AT apoptosis has not been extensively studied, but loss of weight involves both decrease in adipocyte cell size and the number of adipocytes. 44 Cell number can decrease by the reduction in the rate of production of new adipocytes or by apoptosis. 45 However, there are reports from animal studies showing that short-term food restriction alone might not cause apoptosis. 46, 47 In our study, the subjects were examined in the phase of weight maintenance, which naturally may decrease the apoptotic activity in the tissue. AT apoptosis has also been linked to inflammation and especially to the effects of increased TNF-a levels in the AT. 48 The decrease in mRNA expression of TNF receptor superfamily observed in the present study might indicate the post inflammation state in weight maintenance. This is in line with the decrease found in the high-mobility group box 1-gene mRNA expression as well as the monocyte to macrophage differentiation-associated gene mRNA expression. Both of these genes have been suggested to be proinflammatory factors, 49 which may promote inflammatory effects on the tissue level and promote insulin resistance in their part. Interestingly, we found a strong downregulation of the TNMD gene (fold change 0.67) along with weight reduction. Moreover, the expression of TNMD was associated with several characteristics of the metabolic syndrome. Tenomodulin has been suggested to mediate antiangiogenic activity, and its C-terminal extracellular domain modulates endothelial cell proliferation [50] [51] [52] indicating that it also might have a role in the function of ECM. It is also involved in collagen fibril maturation. 53 To our knowledge, this is the first study to show a link between TNMD and characteristics of metabolic syndrome including insulin resistance, but the mechanisms by which tenomodulin may be involved in insulin sensitivity remains to be elucidated. Weight reduction has downregulated the expression of TNMD also in healthy obese subjects. 26 Recently, our studies have shown an association between the TNMD genetic variation and measures of obesity and the risk of T2DM. 54 In a few short-term studies dramatic weight reduction has produced downregulation in the gene expression of inflammation factors, 27 and genes related to desaturation of fatty acids in AT. 26 In cross-sectional studies comparing obese and lean subjects, upregulation of inflammation-related genes in General linear model for univariate analysis for the differences between Groups 1 and 2 corrected with age, gender and weight at baseline. b General linear model for univariate analysis for the differences between the subjects selected for the microarray analysis from the weight reduction and control groups corrected with age, gender and weight at baseline. Figure 2 The fold changes using quantitative real-time PCR (black bars) and microarray (white bars) analysis in subjects whose adipose tissue samples were chosen for microarray analysis from the weight reduction group (n ¼ 9). TNMD ¼ tenomodulin, ADAM12 ¼ A disintegrin metalloproteinase domain 12, PIC4CB ¼ phosphatidylinositol 4-kinase, catalytic b polypeptide, ADCY7 ¼ adenylate cyclase 7, CCND2 ¼ cyclin D2, PRDM4 ¼ pr domain containing 4, PDGFRL ¼ platelet-derived growth factor receptor-like.
Weight reduction and gene expression in AT M Kolehmainen et al AT was found in the obese subjects. 25 Compared with previous studies, our study was long-term, with a follow-up lasting more than 8 months. In addition, the intervention was moderate, resulting in weight loss of about 8%. The long-term moderate weight reduction allows adaptation and compensatory effects to take place. It might, therefore, not be surprising that we detected changes in different gene clusters than what has been reported previously. Our findings are more likely to describe stable long-term changes in AT at the molecular level after the acute changes in the Fold changes (non-significant) of the genes are given also in the control group. Mean(range).
a Values are fold changes: intensity of gene expressed after experiment divided by the intensity at baseline. Genes confirmed by QPCR are marked in bold. The comparisons were made within the groups, paired sample t-test with 100 permutations.
Weight reduction and gene expression in AT M Kolehmainen et al gene expression that occur with short-term substantial weight reduction, and continuing negative energy balance. Previous findings 27 have also shown that different cell types contribute differently to the production or secretion of adipokines and other molecules in AT. Function of different cell types in AT is, however, based on their mutual interaction, which determines the overall impact of AT on disease development. General linear model for the interaction of time and group between the weight reduction and control group. b GLM, interaction of time and group between the subjects who were chosen for the microarray analysis from the weight reduction and control group. Weight reduction and gene expression in AT M Kolehmainen et al
Long-term moderate weight reduction and reduction of fat mass altered the gene expression of subcutaneous AT in humans. Genes involved in the function of the ECM and terminal differentiation of adipocytesFcell death showed a strong downregulation after weight reduction. This likely reflects a new stable state at the molecular level in AT. Further studies are warranted to elucidate the mechanisms of these genetic factors in human pathogenesis of insulin resistance and T2DM.
